Predictive value of hormone measurements in maternal and fetal complications of pregnancy

Endocrine Reviews

Volumn 23, Issue 2, 2002, Pages 230-257

  Reis, Fernando M ^c   D'Antona, Donato ^b   Petraglia, Felice ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN A; ALPHA FETOPROTEIN; BRAIN NATRIURETIC PEPTIDE; CELL ADHESION MOLECULE; CHORIONIC GONADOTROPIN; CORTICOTROPIN RELEASING FACTOR; ESTRIOL; ESTROGEN; GROWTH HORMONE; INHIBIN A; LEPTIN; NEUROSTEROID; PLACENTAL PEPTIDE HORMONE; PREGNANCY ASSOCIATED PLASMA PROTEIN A; PROGESTERONE; PROLACTIN; SOMATOMEDIN;

AMNION; CHORION; CLINICAL EXAMINATION; CYTOKINE PRODUCTION; DECIDUA; DIABETES MELLITUS; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; DOWN SYNDROME; EARLY DIAGNOSIS; FETOPLACENTAL UNIT; FETUS OUTCOME; HORMONE DETERMINATION; HUMAN; INTRAUTERINE GROWTH RETARDATION; MATERNAL CARE; PLACENTA; PREDICTION; PREECLAMPSIA; PREGNANCY COMPLICATION; PREMATURE LABOR; PRENATAL SCREENING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TISSUE DIFFERENTIATION; ULTRASOUND;

EID: 0036222168     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/edrv.23.2.0459     Document Type: Review

References (384)

1. The endocrinology of pregnancy
2. Peptide signaling in human placenta and membranes: Autocrine, paracrine, and endocrine mechanisms
3. Role of corticotropin-releasing hormone in onset of labour
4. Putative role of placental corticotropin-releasing factor in the mechanisms of human parturition
5. The control of labor
6. Inhibin, activin and follistatin in the human placenta - A new family of regulatory proteins
7. Inhibin and activin production in human placenta
8. Neuroendocrine-metabolic regulation of pregnancy
9. Down syndrome
10. Prenatal losses of trisomy 21
11. Parental origin of the extra chromosome in Down's syndrome
12. The origin of human trisomy: A study of heteromorphisms and satellite associations
13. Down syndrome: Perinatal complications and counseling experiences in 216 patients
14. Risk factors for infant mortality in Down's syndrome: A nationwide study
15. Prenatal diagnostic procedures
16. Randomised controlled trial of genetic amniocentesis in 4606 low-risk women
17. Rates of chromosome abnormalities at different maternal ages
18. Revised estimates and projections of Down syndrome births in the United States, and the effects of prenatal diagnosis utilization, 1970-2002
19. An association between low maternal serum α-fetoprotein and fetal chromosomal abnormalities
20. Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum α-fetoprotein level
21. Prenatal diagnosis of neural tube defects. IV. Maternal serum α-fetoprotein screening
22. Maternal serum-α-fetoprotein measurement in antenatal screening for anencephaly and spina bifida in early pregnancy. Report of U.K. collaborative study on α-fetoprotein in relation to neural-tube defects
23. Decreased levels of amniotic fluid α-fetoprotein associated with Down syndrome
24. Fetal hepatic α-fetoprotein mRNA expression in fetuses with trisomy 21 and 18 at 12-15 weeks gestation
25. α-Fetoprotein in fetal serum, amniotic fluid, and maternal serum
26. Use of maternal serum α-fetoprotein measurements to screen for Down's syndrome
27. Placental synthesis of oestriol in Down's syndrome pregnancies
28. Placental estrogen biosynthesis during human pregnancy
29. Low second trimester maternal serum unconjugated oestriol in pregnancies with Down's syndrome
30. Second-trimester unconjugated oestriol levels in maternal serum from chromosomally abnormal pregnancies using an optimized assay
31. Maternal serum unconjugated oestriol as an antenatal screening test for Down's syndrome
32. The heterogeneity of human chorionic gonadotropin (hCG). III. The occurrence and biological and immunological activities of nicked hCG
33. The deactivation of hCG by nicking and dissociation
34. Elevated serum nicked and urinary β-core fragment hCG in preeclamptic pregnancies
35. Human chorionic gonadotropin β-subunit nicking enzymes in pregnancy and cancer patient serum
36. Evaluation of an assay of the free β-subunit of choriogonadotropin and its potential value in screening for Down's syndrome
37. First-trimester α-fetoprotein screening for Down syndrome
38. Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities
39. Maternal serum screening for Down's syndrome in early pregnancy
40. Triple marker (α-fetoprotein, unconjugated estriol, human chorionic gonadotropin) vs. α-fetoprotein plus free-β subunit in second-trimester maternal serum screening for fetal Down syndrome: A prospective comparison study
41. Second-trimester maternal serum screening for Down's syndrome: Free β-human chorionic gonadotrophin (HCG) and α-fetoprotein, with or without unconjugated oestriol, compared with total HCG, α-fetoprotein and unconjugated oestriol
42. Prospective evaluation of free β-subunit of human chorionic gonadotropin and dimeric inhibin A for aneuploidy detection
43. Combining inhibin A with existing second-trimester markers in maternal serum screening for Down's syndrome
44. The use of free β-hCG in antenatal screening for Down's syndrome
45. Second trimester prenatal screening for Down's syndrome using α-fetoprotein and free β hCG: A seven year review
46. High maternal serum chorionic gonadotropin level in Downs' syndrome pregnancies is caused by elevation of both subunits messenger ribonucleic acid level in trophoblasts
47. The placenta in trisomy in the last trimester of pregnancy
48. A single gonadotropin α-subunit gene in normal tissue and tumor-derived cell lines
49. Isolation, cloning and sequence analysis of the cDNA for the α subunit of human chorionic gonadotropin
50. Identification of a promoter region in the CG β gene cluster
51. Advent of maternal serum markers for Down syndrome screening
52. Maternal serum markers for fetal trisomy 21 screening
53. hCG and the free β-subunit as screening tests for Down syndrome
54. Maternal serum Down syndrome screening: Free β-protein is a more effective marker than human chorionic gonadotropin
55. Improved performance in a prenatal screening programme for Down's syndrome incorporating serum-free hCG subunit analyses
56. Maternal serum screening for chromosome defects: Human chorionic gonadotropin vs. its free-β subunit
57. Abnormal maternal serum levels of human chorionic gonadotropin free subunits in trisomy 18
58. Free β human choriogonadotropin in Down's syndrome screening: A multicentre study of its role compared with other biochemical markers
59. First trimester screening for aneuploidy: Serum biochemical markers
60. Screening of maternal serum for fetal Down's syndrome in the first trimester
61. First-trimester maternal serum α-fetoprotein and chorionic gonadotropin in aneuploid pregnancies
62. First-trimester maternal serum human chorionic gonadotrophin as a marker for fetal chromosomal disorders
63. Inhibin: Definition and nomenclature, including related substances
64. The transforming growth factor-β family
65. Inhibin subunits in human placenta: Localization and messenger ribonucleic acid levels during pregnancy
66. Immunohistochemical localization of inhibin/activin subunits in human placenta
67. Presence and synthesis of inhibin subunits in human decidua
68. Inhibin and activin in human fetal membranes: Evidence for a local effect on prostaglandin release
69. Localization, secretion, and action of inhibin in human placenta
70. Measurement of serum concentrations of inhibin-A (α-β A dimer) during human pregnancy
71. Changes in peripheral serum levels of total activin A during the human menstrual cycle and pregnancy
72. Second-trimester maternal serum immunoreactive inhibin as a marker for fetal Down's syndrome
73. Immunoassays for inhibin and its subunits. Further applications of the synthetic peptide approach
74. Second trimester screening for Down's syndrome using maternal serum dimeric inhibin A
75. Inhibin A and pro-α C inhibin in Down syndrome and normal pregnancies
76. Amniotic fluid levels of dimeric inhibins, pro-α C inhibin, activin A and follistatin in Down's syndrome
77. Dimeric inhibin A as a marker for Down's syndrome in early pregnancy
78. Antigenic constituents in pregnancy plasma which are undetectable in normal non-pregnant female or male plasma
79. Double-monoclonal immunofluorometric assays for pregnancy-associated plasma protein A/proeosinophil major basic protein (PAPP-A/proMBP) complex in first-trimester maternal serum screening for Down syndrome
80. Pregnancy-associated plasma protein A: Circulating levels during normal pregnancy
81. Ultrasound and biochemical assessment of the first trimester pregnancy
82. Pregnancy associated plasma protein A as a marker for Down syndrome in the second trimester of pregnancy
83. Screening for Down's syndrome: Changes in marker levels and detection rates between first and second trimesters
84. Gene expression of human pregnancy-associated plasma protein-A in placenta from trisomic pregnancies
85. Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy
86. Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening
87. Evaluation of multiple-marker screening for Down syndrome in a statewide population
88. A prospective evaluation of a second-trimester screening test for fetal Down syndrome using maternal serum α-fetoprotein, hCG, and unconjugated estriol
89. First-trimester aneuploidy screening using serum human chorionic gonadotropin (hCG), free ahCG, and progesterone
90. First-trimester maternal serum biochemical indicators in Down syndrome
91. Low levels of amniotic fluid placental alkaline phosphatase in Down's syndrome
92. Established markers in second trimester maternal serum
93. α-Fetoprotein, free β-human chorionic gonadotropin, and dimeric inhibin A produce the best results in a three-analyte, multiple-marker screening test for fetal Down syndrome
94. First-trimester screening for aneuploidy: Research or standard of care?
95. Women's opinions and the implications of first- vs. second-trimester screening for fetal Down's syndrome
96. Antenatal screening for Down's syndrome
97. Fetal nuchal translucency: Ultrasound screening for chromosomal defects in first trimester of pregnancy
98. First trimester screening for aneuploidy: Nuchal translucency sonography
99. Fetal nuchal translucency: Ultrasound screening for fetal trisomy in the first trimester of pregnancy
100. Evaluation of first-trimester screening by fetal nuchal translucency and maternal age
101. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation
102. Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome
103. Birth weight of relatives by maternal tendency to repeat small-for-gestational-age (SGA) births in successive pregnancies
104. Etiologies of fetal growth restriction
105. Intrauterine growth retardation
106. Reduction of false-positive diagnosis of fetal growth restriction by application of customized fetal growth standards
107. Customized fetal weight limits for antenatal detection of fetal growth restriction
108. Adjustment of birth weight standards for maternal and infant characteristics improves the prediction of outcome in the small-for-gestational-age infant
109. Cerebral palsy in infants with asymmetric growth restriction
110. Current concepts of fetal growth restriction. I. Causes, classification, and pathophysiology
111. Chromosome studies in investigation of stillbirths and neonatal deaths
112. Causes of intrauterine growth restriction
113. The prediction of fetal growth retardation in twin pregnancy
114. Ultrasound in twin pregnancy
115. Vascular anomalies of the umbilical cord. I. Obstetric implications
116. Placenta previa. Predisposing factors and effects on the fetus and surviving infants
117. The relative contributions of different maternal factors in small-for-gestational-age pregnancies
118. The effect of hypertension in pregnancy on fetal and neonatal condition
119. Fetal growth retardation in cigarette-smoking mothers is not due to decreased maternal food intake
120. Maternal smoking affects fetal growth more in the male fetus
121. Pattern of malformation in offspring of chronic alcoholic mothers
122. Foetal nutrition, foetal growth restriction and health later in life
123. Pre-pregnancy risk factors of small-for-gestational-age births and perinatal mortality
124. Placental expression of vascular endothelial growth factor in placentae from pregnancies complicated by pre-eclampsia and intrauterine growth restriction does not support placental hypoxia at delivery
125. Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen - A review
126. Structural analysis of placental terminal villi from growth-restricted pregnancies with abnormal umbilical artery Doppler waveforms
127. Fetal growth retardation and pre-eclampsia
128. Fetal outcome in hypertensive disorders of pregnancy
129. Markers of intravascular coagulation and fibrinolysis in preeclampsia: Association with intrauterine growth retardation
130. Hemostatic variables as independent predictors for fetal growth retardation in preeclampsia
131. Placental apoptosis in preeclampsia
132. Immunohistochemical evaluation of apoptosis in placentae from normal and intrauterine growth-restricted pregnancies
133. Increased placental apoptosis in intrauterine growth restriction
134. The clinical prediction of intrauterine growth retardation
135. Determinants of low birth weight: Methodological assessment and meta-analysis
136. Intrauterine growth retardation and fetal cardiac function
137. Levels and patterns of intrauterine growth retardation in developing countries
138. Birthweight and perinatal mortality. III. Towards a new method of analysis
139. Screening for light-for-gestational age infants: A comparison of three simple measurements
140. Intrauterine growth retardation
141. Fetal malnutrition: Its incidence, causes, and effects
142. Morbidity and mortality among very-low-birth-weight neonates with intrauterine growth restriction
143. Fetal and infant origin of adult disease
144. Childhood influences on adult health: A review of recent work from the British I946 national birth cohort study, the MRC National Survey of Health and Development
145. Placental protein measurements in complicated pregnancies. I. Intrauterine growth retardation
146. Current status of estrogen assays in obstetrics and gynecology. 2. Estrogen assays in late pregnancy
147. Further investigation on the predictive value of human placental lactogen in high-risk pregnancies
148. Maternal serum concentrations of human placental lactogen, estradiol and pregnancy specific β 1-glycoprotein and fetal growth retardation
149. Oxytocinase and human placental lactogen for the prediction of intrauterine growth retardation
150. Maternal blood levels of human placental lactogen in the prediction of fetal growth retardation: Choosing a cut-off point between normal and abnormal
151. Dehydroepiandrosterone sulfate loading test in the diagnosis of complicated pregnancies
152. The association between unexplained second-trimester maternal serum hCG elevation and pregnancy complications
153. Fetal growth in patients with elevated maternal serum hCG levels
154. Predictive value of early human chorionic gonadotrophin serum profiles for fetal growth retardation
155. Maternal serum human chorionic gonadotropin level at fifteen weeks is a predictor for preeclampsia
156. An association between elevated levels of human chorionic gonadotropin in the midtrimester and adverse pregnancy outcome
157. Doppler velocimetry of the umbilical artery as a predictor of outcome in pregnancies characterized by elevated β-subunit human chorionic gonadotropin
158. Maternal urine β-core hCG fragment level and small for gestational age neonates
159. Midtrimester urine human chorionic gonadotropin β-subunit core fragment levels and the subsequent development of preeclampsia
160. Fetal growth retardation and second trimester maternal serum human chorionic gonadotrophin levels
161. Third-trimester maternal serum β-hCG level and umbilical blood flow in fetal growth retardation
162. The human placental lactogen genes: Structure, function, evolution and transcriptional regulation
163. Small-for-gestational-age (SGA) infants born at term: Growth and development during the first year of life
164. Human placental lactogen in preeclampsia
165. The efficacy of biochemical assays in assessing an IUGR risk-group, preselected with ultrasound fetometry
166. Human placental lactogen and pregnancy-associated plasma protein A in first trimester and subsequent fetal growth
167. Feto-placental steroid metabolism in growth retarded human fetuses
168. Association of low unconjugated estriol in the second trimester and adverse pregnancy outcome
169. Second-trimester maternal serum marker screening: Maternal serum α-fetoprotein, β-human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome
170. Antenatal biochemical screening to predict low birthweight infants
171. Urinary steroid levels in newborn infants with intrauterine growth retardation
172. Serum dehydroepiandrosterone sulfate in premature infants and infants with intrauterine growth retardation
173. Relationship of maternal placental blood flow to the placental clearance of maternal plasma dehydroisoandrosterone sulfate through placental estradiol formation
174. Comparison of uteroplacental blood flow in normal and in intrauterine growth-retarded pregnancy. Measurements with Indium-113 m and a computer-linked gammacamera
175. A human placental GH: Increasing levels during second half of pregnancy with pituitary GH suppression as revealed by monoclonal antibody radioimmunoassays
176. The physiology of growth hormones (GHs) in pregnant women and partial characterization of the placental GH variant
177. Syncytiotrophoblastic localization of the human growth hormone variant mRNA in the placenta
178. A specific growth hormone-binding protein in human plasma: Initial characterization
179. Characterization of the growth hormone-binding protein of human serum using a panel of monoclonal antibodies
180. Growth hormone-binding protein in normal and pathologic gestation: Correlations with maternal diabetes and fetal growth
181. Continuing growth and development of the third-trimester human placenta
182. Placental growth hormone (GH), GH-binding protein, and insulin-like growth factor axis in normal, growth-retarded, and diabetic pregnancies: Correlations with fetal growth
183. Placental growth hormone levels in normal pregnancy and in pregnancies with intrauterine growth retardation
184. Decreased expression of placental growth hormone in intrauterine growth retardation
185. The role of insulin-like growth factor-I and insulin-like growth factor-binding protein-1 in the control of human fetal growth
186. Insulin-like growth factors (IGF) 1 and 2 in human foetal plasma and relationship to gestational age and foetal size during midpregnancy
187. The somatomedins: Insulin-like growth factors
188. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r)
189. A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting
190. Insulin-like growth factor I gene deletion causing intrauterine growth retardation and severe short stature
191. Endocrine and substrate control of fetal growth: Placental and maternal influences and insulin-like growth factors
192. Circulating levels of IGF-I and IGF-binding protein-1 throughout pregnancy: Relation to birth-weight and maternal weight
193. Somatomedin levels in pregnancy: Longitudinal Study in healthy subjects and patients with growth hormone deficiency
194. Regulation of maternal IGF-I by placental GH in normal and abnormal human pregnancies
195. Growth hormone, insulin-like growth factor I and its binding proteins 1 and 3 in last trimester intrauterine growth retardation with increased pulsatility index in the umbilical artery
196. A prospective study of maternal serum insulin-like growth factor-I in pregnancies with appropriately grown or growth restricted fetuses
197. Fetal and maternal plasma insulin-like growth factors and binding proteins in pregnancies with appropriate or retarded fetal growth
198. Insulin-like growth factor I in fetal serum obtained by cordocentesis is correlated with intrauterine growth retardation
199. Serum insulin-like growth factor binding protein-1 at 16 weeks and subsequent preeclampsia
200. Obese and diabetes: Two mutant genes causing diabetes-obesity syndromes in mice
201. Positional cloning of the mouse obese gene and its human homologue
202. Serum immunoreactive-leptin concentrations in normal-weight and obese humans
203. Serum leptin concentration, obesity, and insulin resistance in Western Samoans: Cross sectional study
204. Neuroendocrine regulation and actions of leptin
205. Placental leptin: An important new growth factor in intrauterine and neonatal development?
206. Leptin production by hydatidiform mole
207. Nonadipose tissue production of leptin: Leptin as a novel placenta-derived hormone in humans
208. Free leptin, bound leptin, and soluble leptin receptor in normal and diabetic pregnancies
209. Leptin in human pregnancy: The relationship with gestational hormones
210. Leptin production and release in the dually in vitro perfused human placenta
211. Adipose tissue growth patterns during human gestation: A histometric comparison of buccal and gluteal fat depots
212. Ontogeny of leptin in human fetuses and newborns: Effect of intrauterine growth retardation on serum leptin concentrations
213. Levels of leptin in maternal serum, amniotic fluid, and arterial and venous cord blood: Relation to neonatal and placental weight
214. Serum leptin concentrations during pregnancy and their relationship to fetal growth
215. Ontogeny of serum leptin concentrations in the human
216. Maternal serum leptin concentrations do not correlate with cord blood leptin concentrations in normal pregnancy
217. Fetal plasma leptin concentrations: Relationship with different intrauterine growth patterns from 19 weeks to term
218. Leptin levels in maternal and cord serum: Relationship with fetal development and placental weight
219. Current concepts of fetal growth restriction. II. Diagnosis and management
220. Uteroplacental blood flow. The story of decidualization, menstruation, and trophoblast invasion
221. Report of the National High Blood Pressure Education Program Working Group on high blood pressure in pregnancy
222. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems (Cochrane review)
223. Anti-platelet agents for preventing and treating preeclampsia
224. Randomised clinical trials of fish oil supplementation in high risk pregnancies
225. Effect of antioxidants on the occurrence of preeclampsia in women at increased risk: A randomised trial
226. Prevention of preeclampsia: A randomized trial of atenolol in hyperdynamic patients before onset of hypertension
227. Early detection of preeclampsia
228. Qualitative assessment of uteroplacental blood flow: Early screening test for high-risk pregnancies
229. Doppler ultrasound of the uterine arteries: The importance of bilateral notching in the prediction of preeclampsia, placental abruption or delivery of a small-for-gestational-age baby
230. One-stage screening for pregnancy complications by color Doppler assessment of the uterine arteries at 23 weeks' gestation
231. Significance ofa diastolic notch in the uterine artery flow velocity waveform induced by uterine embolisation in the pregnant ewe
232. How useful is uterine artery Doppler flow velocimetry in the prediction of preeclampsia, intrauterine growth retardation and perinatal death? An overview
233. A prospective study of several potential biologic markers for early prediction of the development of preeclampsia
234. Early detection of preeclampsia
235. Etiology and pathogenesis of preeclampsia: Current concepts
236. Oxygen regulates human cytotrophoblast differentiation and invasion: Implications for endovascular invasion in normal pregnancy and in preeclampsia
237. Invasive cytotrophoblast apoptosis in preeclampsia
238. Preeclampsia: An excessive maternal inflammatory response to pregnancy
239. Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFβ(3)
240. Hypoxia alters early gestation human cytotrophoblast differentiation/invasion in vitro and models the placental defects that occur in preeclampsia
241. Oxygen and placental development during the first trimester: Implications for the pathophysiology of preeclampsia
242. Elevated serum human chorionic gonadotropin as evidence of secretory response in severe preeclampsia
243. Pathologic findings in pregnancies with unexplained increases in midtrimester maternal serum human chorionic gonadotropin levels
244. Expression of G proteins in human placentas from pregnancies complicated by gestational hypertension
245. Second-trimester levels of maternal serum human chorionic gonadotropin and inhibin a as predictors of preeclampsia in the third trimester of pregnancy
246. Elevated second trimester human chorionic gonadotropin level associated with adverse pregnancy outcome
247. The value of elevated second-trimester β-human chorionic gonadotropin in predicting development of preeclampsia
248. Validity in nulliparas of increased β-human chorionic gonadotrophin at mid-term for predicting pregnancy-induced hypertension complicated with proteinuria and intrauterine growth retardation
249. Second trimester serum free β human chorionic gonadotrophin levels as a predictor of preeclampsia
250. Midtrimester N-terminal proatrial natriuretic peptide, free β hCG, and α-fetoprotein in predicting preeclampsia
251. The association between hypertensive disorders of pregnancy and abnormal second-trimester maternal serum levels of hCG and α-fetoprotein
252. Elevated midtrimester maternal serum hCG in chromosomally normal pregnancies is associated with preeclampsia and velamentous umbilical cord insertion
253. Maternal serum human chorionic gonadotropin level at fifteen weeks as a predictor for preeclampsia?
254. Increased maternal serum activin A but not follistatin levels in pregnant women with hypertensive disorders
255. Comparison of maternal serum total activin A and inhibin A in normal, preeclamptic, and nonproteinuric gestationally hypertensive pregnancies
256. Hypertension in pregnancy: Changes in activin A maternal serum concentration
257. Serum activin A and inhibin A elevated in preeclampsia: No relation to insulin sensitivity
258. Activin A and inhibin A as possible endocrine markers for preeclampsia
259. Inhibin A, and activin A levels in the second trimester as predictors of preeclampsia
260. Serum inhibin A and activin A are elevated prior to the onset of preeclampsia
261. Inhibin expression in normal and preeclamptic placental tissue
262. Activin is a local regulator of human cytotrophoblast cell differentiation
263. Prediction of preeclampsia with maternal mid-trimester total renin, inhibin A, AFP and free β-hCG levels
264. Serum levels of activin A and inhibin A and the subsequent development of preeclampsia
265. Maternal serum inhibin A can predict preeclampsia
266. Second-trimester maternal serum inhibin A concentration as an early marker for preeclampsia
267. Raised maternal serum inhibin A concentration at 10 to 14 weeks of gestation is associated with preeclampsia
268. Correlation between second trimester maternal serum inhibin-A and human chorionic gonadotrophin for the prediction of preeclampsia
269. Plasma renin activity and aldosterone serum concentration are decreased in severe preeclampsia but not in the HELLP-syndrome
270. Plasma active renin, angiotensin I, and angiotensin II during pregnancy and in preeclampsia
271. Determination of renin, angiotensin converting enzyme and angiotensin II levels in human placenta, chorion and amnion from women with pregnancy induced hypertension
272. A study of angiotensin II pressor response throughout primigravid pregnancy
273. The value of the angiotensin sensitivity test in the early diagnosis of hypertensive disorders in pregnancy
274. The angiotensin sensitivity test and low-dose aspirin are ineffective methods to predict and prevent hypertensive disorders in nulliparous pregnancy
275. Platelet angiotensin II binding sites and early detection of preeclampsia
276. A prospective longitudinal study of platelet angiotensin II receptors for the prediction of preeclampsia
277. Early prediction of preeclampsia by measurement of kallikrein and creatinine on a random urine sample
278. An increase of the plasma N-terminal peptide of proatrial natriuretic peptide in preeclampsia
279. Relative abundance of placental pro-atrial natriuretic factor mRNA in normal pregnancy and preeclampsia
280. Endothelin-1 in feto-placental tissues from normotensive pregnant women and women with preeclampsia
281. Expression and relationship between endothelin-1 messenger ribonucleic acid (mRNA) and inducible/endothelial nitric oxide synthase mRNA isoforms from normal and preeclamptic placentas
282. Plasma endothelin-1 and mean arterial pressure in the prediction of preeclampsia
283. Vasoactive mediators in pregnancy-induced hypertensive disorders: A longitudinal study
284. Excessive placental secretion of neurokinin B during the third trimester causes preeclampsia
285. 5-α-Dihydroprogesterone formation in human placenta from 5α-pregnan-3β/α-ol-20-ones and 5-pregnan-3β-yl-20-one sulfate
286. Circulating maternal serum progesterone in high-risk pregnancies
287. Hormone production during pregnancy in the primigravid patient. I. Plasma levels of progesterone and 5-α-pregnane-3,20-dione throughout pregnancy of normal women and women who developed pregnancy-induced hypertension
288. Serum allopregnanolone levels in pregnant women: Changes during pregnancy, at delivery, and in hypertensive patients
289. Expression of adhesion molecules by endovascular trophoblast and decidual endothelial cells: Implications for vascular invasion during implantation
290. A comparative study of serum soluble vascular cell adhesion molecule-1 and soluble intercellular adhesion molecule-1 in preeclampsia
291. Soluble intercellular adhesion molecule-1 serum profile in physiologic and preeclamptic pregnancy
292. Increased levels of intercellular adhesion molecules and vascular cell adhesion molecules in preeclampsia
293. Preeclampsia does not change the adhesion molecule status in the placental bed
294. Evidence for local stimulation of ACTH secretion by corticotropin-releasing factor in human placenta
295. Reproductive placental corticotropin-releasing hormone and its clinical implications
296. Processing of procorticotropin-releasing hormone (pro-CRH): Molecular forms of CRH in normal and preeclamptic pregnancy
297. The effect of preeclampsia on human placental corticotrophin-releasing hormone content and processing
298. Analysis of mid-trimester corticotrophin-releasing hormone and α-fetoprotein concentrations for predicting preeclampsia
299. High levels of corticotropin-releasing factor (CRF) are inversely correlated with low levels of maternal CRF-binding protein in pregnant women with pregnancy-induced hypertension
300. Alterations of maternal and fetal leptin concentrations in hypertensive disorders of pregnancy
301. Longitudinal analysis of maternal plasma leptin concentrations during normal pregnancy and preeclampsia
302. Free leptin is increased in normal pregnancy and further increased in preeclampsia
303. Decreased maternal serum leptin in pregnancies complicated by preeclampsia
304. Augmented placental production of leptin in preeclampsia: Possible involvement of placental hypoxia
305. Preeclampsia disrupts the normal relationship between serum leptin concentrations and adiposity in pregnant women
306. Can antenatal clinical and biochemical markers predict the development of severe preeclampsia?
307. The HELLP syndrome: Its association with unexplained elevation of MSAFP and MShCG in the second trimester
308. The importance of preterm births for peri- and neonatal mortality in rural Malawi
309. Infant mortality statistics from the 1998 period linked birth/infant death data set
310. The contribution of mild and moderate preterm birth to infant mortality
311. The epidemiological transition in maternal and child health in a Brazilian city, 1982-93: A comparison of two population-based cohorts
312. Intrauterine infection and preterm delivery
313. Vaginal fetal fibronectin measurements from 8 to 22 weeks' gestation and subsequent spontaneous preterm birth
314. Cervicovaginal fetal fibronectin as a marker for preterm delivery: A meta-analysis
315. The preterm prediction study: Fetal fibronectin testing and spontaneous preterm birth
316. Endocrine and paracrine regulation of birth at term and preterm
317. The preterm prediction study: Granulocyte colony-stimulating factor and spontaneous preterm birth
318. Interleukin-1α, interleukin-6 and interleukin-8 in cervico/vaginal secretion for screening of preterm birth in twin gestation
319. Detection of tumor necrosis factor-α, interleukin-6, and fetal fibronectin in the lower genital tract during pregnancy: Relation to outcome
320. Maternal serum interleukin 1, 2, 6, 8 and interleukin-2 receptor levels in preterm labor and delivery
321. Maternal serum interleukin-6 during pregnancy and during term and preterm labor
322. Amniotic fluid interleukin-6 and interleukin-8 levels predict the success of tocolysis in patients with preterm labor
323. Increased interleukin-6 concentrations in cervical secretions are associated with preterm delivery
324. A fetal systemic inflammatory response is followed by the spontaneous onset of preterm parturition
325. Elevated maternal plasma corticotropin-releasing hormone levels in pregnancies complicated by preterm labor
326. The diagnosis of preterm labor and the prediction of preterm delivery
327. Maternal plasma corticotropin-releasing hormone associated with stress at 20 weeks' gestation in pregnancies ending in preterm delivery
328. Elevated mid-trimester maternal corticotrophin-releasing hormone levels in pregnancies that delivered before 34 weeks
329. Corticotropin-releasing factor and its binding protein: Maternal serum levels in term and preterm deliveries
330. Predicting risk of preterm delivery by second-trimester measurement of maternal plasma corticotropin-releasing hormone and α-fetoprotein concentrations
331. Angiogenin: A marker for preterm delivery in midtrimester amniotic fluid
332. Activin at parturition: Changes of maternal serum levels and evidence for binding sites in placenta and fetal membranes
333. 2
334. Regulation of activin A, inhibin A, and follistatin production in human amnion and choriodecidual explants by inflammatory mediators
335. Concentrations of activin A, inhibin A and follistatin in human amnion, choriodecidual and placental tissues at term and preterm
336. Corticotropin-releasing hormone, corticotropin-releasing hormone-binding protein, and activin A in maternal serum: Prediction of preterm delivery and response to glucocorticoids in women with symptoms of preterm labor
337. Factors associated with preterm labour and changes in the cervix before labour in twin pregnancy
338. Increased saliva oestriol to progesterone ratio before preterm delivery: A possible predictor for preterm labor?
339. Accuracy of salivary estriol testing compared to traditional risk factor assessment in predicting preterm birth
340. Salivary estriol as risk assessment for preterm labor: A prospective trial
341. Serial salivary estriol to detect an increased risk of preterm birth
342. Elevated second-trimester maternal serum hCG alone or in combination with elevated α-fetoprotein
343. Adverse obstetric outcome in low- and high-risk pregnancies: Predictive value of maternal serum screening
344. Is cervicovaginal β-human chorionic gonadotropin a predictor of successful induction of labor at term?
345. Using fasting plasma glucose concentrations to screen for gestational diabetes mellitus: Prospective population based study
346. Criteria for screening tests for gestational diabetes
347. Impact of prenatal glucose screening on the diagnosis of gestational diabetes and on pregnancy outcomes
348. Macrosomia - Maternal and fetal risk factors
349. Maternal fructosamine and glycosylated haemoglobin in the prediction of gestational glucose intolerance
350. Gestational diabetes: Should it be added to the syndrome of insulin resistance?
351. Excessive secretion of insulin precursors characterizes and predicts gestational diabetes
352. CAP, HCS and urinary oestriol assays in diabetic pregnancy
353. Second-trimester serum chorionic gonadotropin concentrations and complications and outcome of pregnancy
354. Fetal macrosomia: Prediction, risks, proposed management
355. Macrosomia in pregnancy complicated by insulin-dependent diabetes mellitus
356. Somatomedins and insulin in diabetic pregnancies: Effects on fetal macrosomia in the human and rhesus monkey
357. Prophylactic insulin treatment of gestational diabetes reduces the incidence of macrosomia, operative delivery, and birth trauma
358. Clinical and ultrasound prediction of macrosomia in diabetic pregnancy
359. Sonographic EFW and macrosomia: Is there an optimum formula to predict diabetic fetal macrosomia?
360. Correctly identifying the macrosomic fetus: Improving ultrasonography-based prediction
361. Placental leptin in normal, diabetic and fetal growth-retarded pregnancies
362. Effects of gestational diabetes on human placental glucose uptake, transfer, and utilisation
363. Detection of placental growth hormone variant and chorionic somatomammotropin-L RNA expression in normal and diabetic pregnancy by reverse transcriptase-polymerase chain reaction
364. Glucose transporter (Glut1, Glut3) mRNA in human placenta of diabetic and non-diabetic pregnancies
365. Comparison of immunoreactive gonadotropin-releasing hormone and human chorionic gonadotropin in term placentas from normal women and those with insulin-dependent and gestational diabetes
366. Gestational diabetes mellitus and paradoxical fetal macrosomia - A case report
367. Mechanisms of in utero overgrowth
368. Insulin-like growth factors, their binding proteins, and fetal macrosomia in offspring of nondiabetic pregnant women
369. Insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBP-1, -2 and -3) in diabetic pregnancy: Relationship to macrosomia
370. Insulin-like growth factors I and II peptide and messenger RNA levels in macrosomic infants of diabetic pregnancies
371. Growth promoting peptides in diabetic and non-diabetic pregnancy: Interactions with trophoblastic receptors and serum carrier proteins
372. Insulin-like growth factors in fetal macrosomia with and without maternal diabetes
373. Expression of insulin-like growth factor II in human placentas from normal and diabetic pregnancies
374. Plasma leptin in infants: Relations to birth weight and weight loss
375. Leptin concentrations in maternal serum and cord blood: Relationship to maternal anthropometry and fetal growth
376. Cord leptin level and fetal macrosomia
377. Macrosomia revisited: Ponderai index and leptin delineate subtypes of fetal overgrowth
378. Increased plasma leptin in gestational diabetes
379. Relative hypoleptinaemia in women with mild gestational diabetes mellitus
380. Fibroblast growth factor 2 is elevated in term maternal and cord serum and amniotic fluid in pregnancies complicated by diabetes: Relationship to fetal and placental size
381. Alterations in circulating human chorionic gonadotropin free α-subunit in insulin-dependent diabetic pregnancy: Correlation with maternal characteristics
382. Discovery of new inducible genes in in vitro decidualized human endometrial stromal cells using microarray technology
383. Misleading authors' inferences in obstetric diagnostic test literature